[Muromonab CD3].
Akioka
Yuko
Y
Department of Pediatric Nephrology, Kidney Center, Tokyo Women's Medical University
Hattori
Motoshi
M
Ito
Katsumi
K
D000208:Acute Disease; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D017252:CD3 Complex / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D016030:Kidney Transplantation; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects; D011654:Pulmonary Edema / Q000209:etiology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell